Date: 2012-05-15
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: results
Company: Pluristem Therapeutics (Germany)
Product: PLX cells (PLacental eXpanded cells)
Action mechanism:
Disease: diabetic-induced diastolic dysfunction
Therapeutic area: Cardiovascular diseases
Country:
Trial details:
Latest
news: Pluristem Therapeutics has announced that cardiac function in a diabetic-induced diastolic dysfunction in animals improved following PLacental eXpanded (PLX cells) administration. The study was conducted as part of the European Commission’s Seventh Framework Program (FP7) in collaboration with Professor Doctor Carsten Tschöpe and his staff at the Charite Universitaetsmedizin Berlin, Berlin-Bradenburg Center for Regenerative Therapies (BCRT), Berlin, Germany. .
Diabetes was induced in thirty-six C57b/6 mice, which resulted in the development of diastolic heart failure. After seven days, the animals received either PLX cells from two separate batches or placebo (12 subjects in each of the three groups). Ten mice were not treated (controls).
After twenty-one days, several cardiac parameters were assessed and found to be significantly improved following the treatment with PLX cells. Important measurements included the cardiac ejection fraction and the left ventricular (LV) relaxation time constant, believed to be the best index of LV diastolic function and a determination of the stiffness of the ventricle.
Cardiac ejection fraction improved 19%, the left ventricular (LV) relaxation time constant decreased 16% and the stiffness of the ventricle decreased 19%.
Additionally, the administration of either batch of PLX cells resulted in a significant anti-inflammatory effect, documented by findings including a significant down regulation of the left ventricular vascular cell adhesion inflammatory mediator-1 (LV VCAM-1) and a significant up regulation of the left ventricular interleukin-10 anti-inflammatory mediator (LV IL-10).
